Q-omics provides the consensus-scored MRPL49 profile across patient tissues and cancer cell-line models. MRPL49 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPL49 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, MRPL49 RNA expression shows 19,300 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where MRPL49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL49 survival associations across molecular data types. MRPL49 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL49 RNA expression–survival associations across cancer types. High MRPL49 expression shows unfavorable associations in PAAD, LAML, ACC and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPL49 RNA expression.
This table summarizes MRPL49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL49 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in BLCA, LIHC and HNSC. The THCA box plot shows higher MRPL49 RNA expression in normal versus tumor tissue (log2 FC = −0.711, t-test p < 0.001).
This table shows molecular features associated with MRPL49 in patient tissues and cancer cell lines. In patient samples, MRPL49 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL49 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
